^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IMM2505

i
Other names: IMM2505
Associations
Trials
Company:
ImmuneOnco Biopharma, SunHo BioPharma
Drug class:
PD-L1 inhibitor, CD47 inhibitor
Related drugs:
Associations
Trials
3d
IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy. (PubMed, Heliyon)
In mouse transplantation models, compared with the first-generation CD47/PD-L1 BsAb (IMM2505), IMM2520 exhibited stronger and dose-dependent antitumor activity. These findings imply that IMM2520 may offer a novel therapeutic alternative for cancer patients.
Journal
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
IMM2505 • IMM2520
over1year
Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2520, targeting both PD-L1 and CD47 as cancer immunotherapy (AACR 2023)
Interestingly, IMM2520 demonstrated a potent and significantly higher anti-tumor activities than IMM01 (a SIRPα-Fc fusion protein) and IMM2505 (also a CD47XPD-L1 mAb-Trap, but the variable region sequence of this PD-L1 antibody is identical to atezolizumab). In another in vivo efficacy study with MC38-hCD47/hPD-L1 colon cancer model, IMM2520 demonstrated a significant anti-tumor activity in a dose-dependent manner at doses between 2 mg/kg to 20 mg/kg. Given its potent preclinical anti-tumor activity as well as the favorable safety profile, IMM2520 may serve as a potent immunotherapy for multiple cancer types by targeting PD-L1 and CD47 on tumor cells.
Preclinical
|
SIRPA (Signal Regulatory Protein Alpha)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • IMM2505 • IMM2520 • timdarpacept (IMM01)